Funding Opportunity PAS-18-557 from the NIH Guide for Grants and Contracts. HIV+ alcohol users remain at high risk for medication non-adherence and rapid disease progression, medication toxicities, organ failure, and poor viremic control, leading to increased risk of transmission and premature death. Recent advances in technology and biomedical science (e.g., new pharmacological agents, alcohol and inflammation biomarkers, internet and mobile technology) open new opportunities for strengthening the quality of HIV/alcohol-related implementation research through utilization of novel technology and biomarkers. This initiative seeks to advance knowledge on implementation and comparative effectiveness of alcohol-focused interventions among HIV+ individuals. Multiple factors need to be investigated, including potentially important patient and provider characteristics, and the organizational, financial, and structural factors that facilitate or inhibit the delivery of evidence-based services for HIV+ individuals with a range of severity of alcohol use problems. The overall goal is to inform clinical decision-making to implement effective interventions that will improve prevention, care, and outcomes across the continuum of HIV and alcohol problem severity and patterns of alcohol use. This solicitation is divided into two major topics. An application may choose to address one or both. These topics include: 1) comparative effectiveness research focused on understanding factors related to early detection, patient engagement and retention in appropriate alcohol and HIV care, and achieving and maintaining optimal treatment responses in diverse settings, and 2) modeling and testing alternative implementation approaches to improve uptake and scaling-up of effective interventions and reduce HIV disease transmission and progression.

Biomedical or quantitative science, Information Systems, Bioinformatics, Biomedical Informatics, Computer Science, or comparable field....
From Medical College of Wisconsin - Tue, 02 Jan 2018 09:07:57 GMT - View all Milwaukee, WI jobs

The project involves surgical induction of stroke and brain trauma, proteomic and molecular analysis, and bioinformatics. Position Vacancy ID:....
From University of Wisconsin–Madison - Thu, 28 Dec 2017 23:50:58 GMT - View all Madison, WI jobs

Negotiable: Paramount Recruitment: Cancer Bioinformatician 100,000 Genomes Project - Cancer Genomics - Competitive salary! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Negotiable: Paramount Recruitment: Director of Bioinformatics & Computational Biology Genomics, Leadership, Target Discovery, NGS, Research Department A fantastic new Director level position has become available with a Top research-driven pharmaceutical company in South-West Germany. Biberach an der Riß, Germany

Negotiable: Paramount Recruitment: Commercial Partnerships Manager Bioinformatics, Genomics, Central London - 100,000 Genomes Project - Commercial Division! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Geno London, England

Master’s degree in Bioinformatics, Computer Science, Computational/ Systems Biology, or a related field. Minimum of 2 years of experience with Next Generation...
From PreventionGenetics - Sun, 24 Dec 2017 09:16:39 GMT - View all Marshfield, WI jobs

Master’s degree in Bioinformatics, Computer Science, Computational/ Systems Biology, or a related field. Minimum of 2 years of experience with Next Generation...
From PreventionGenetics, LLC - Sun, 24 Dec 2017 06:09:03 GMT - View all Marshfield, WI jobs

Funding Opportunity PAR-18-550 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use.

Funding Opportunity PAR-18-548 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is encourage applications from Small Business Concerns (SBCs) to support rigorous clinical validation of a candidate biomarker using retrospective and/or prospective methods in a manner that is consistent with the purpose of the biomarker. This FOA assumes that: 1) a candidate biomarker has already been identified, 2) an analytical method has been developed and validated that is consistent with the purpose of the biomarker and 3) a working hypothesis regarding context of use is in place. The goal of this FOA is to facilitate the advancement of robust and reliable biomarkers of neurological disease for use in multi-site clinical trials and clinical practice.

Funding Opportunity PAR-18-549 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support applications from Small Business Concerns (SBCs) to perform rigorous analytical validation of candidate biomarker measures or endpoints in a manner that is consistent with FDA guidelines. Analytical validation establishes that the performance characteristics of the biomarker measurement or endpoint are acceptable for its intended use.

Notice NOT-RM-18-008 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-17-044 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit revision applications from currently funded International Centers of Excellence for Malaria Research (ICEMR) investigators. These awards will support the conduct and oversight of observational studies or implementation studies to evaluate the impact of in-country, approved vector control and malaria prevention interventions on the incidence, prevalence, and transmission of malaria. This program will leverage the baseline data, infrastructure, and capacity established by the ICEMRs. The studies will augment or use the established malaria surveillance systems to study the impact of the vector control and malaria prevention interventions on human health outcomes. This FOA solicits three distinct types of studies: Study Type 1 is a Controlled study, Study Type 2 is an Observational study, and Study Type 3 is an Implementation study. Applications may propose projects for one of each Study Type.

Funding Opportunity RFA-HL-19-008 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to advance knowledge of the HIV infection, with a focus on HIV-related comorbidities by supporting current Clinical Research Sites (CRS) of the Multi-Center AIDS Cohort Study (MACS) and the Womens Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS). Through this FOA each CRS will implement the full MACS/WIHS-CCS unified science agenda and provide expertise to lead part of the unified science agenda (e.g., protocol development, as a reading center, or laboratory). Targeted recruitment will be supported with justification. A companion cooperative agreement will support the MACS/WIHS-CCS Data Analysis and Coordination Center (DACC).

Notice NOT-MD-18-003 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HL-19-007 from the NIH Guide for Grants and Contracts. The purpose of this limited competition Funding Opportunity Announcement (FOA) is to support a Data Analysis and Coordination Center (DACC) for the Multicenter AIDS Cohort Study (MACS) and the Womens Interagency HIV Study (WIHS) Combined Cohort Study (MACS/WIHS-CCS). The DACC will work as a member of the MACS/WIHS-CCS consortium to advance knowledge of basic and clinical science, and the epidemiology of HIV infection in the US, with a focus on HIV-related comorbidities. A companion cooperative agreement will support MACS/WIHS-CCS Clinical Research Sites (CRS)

Notice NOT-OD-18-115 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-18-552 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to invite U01 grant applications focused on advancing the understanding of mechanisms mediating aging in cancer. Qualifying applications must propose aging in cancer studies that are collaborations between non-NIH Principal Investigators (PIs) and intramural PIs from NCI and/or NIA as a co-investigator.

Negotiable: Paramount Recruitment: Software Engineer - NGS London A great opportunity is available for a scientific software developer to join a highly talented team based in London who are integrating cutting-edge semiconductor technologies with novel biochemical techniques to develop a London, England

Negotiable: Paramount Recruitment: Head of Bioinformatics Research Services London Paramount are working in partnership with Genomics England to expand their team in order to deliver success Paramount are working in partnership with Genomics England to expand their team in order to with t London, England